Natalie Bhatt

Natalie Bhatt investigates shared oncogenic mutations as targets for off-the-shelf TCR-based immunotherapies. Her research has focused on identifying TCRs specific for common driver mutations such as KRAS G12D/V and TP53 hotspots. She has characterized the HLA restriction elements and TCR requirements for recognizing these shared neoantigens. Her work is advancing the development of allogeneic cell therapies that could benefit large patient populations without requiring personalized manufacturing.